Immune reconstitution from peripheral blood mononuclear cells inhibits lung carcinoma growth in NOD/SCID mice

Liu,Xiang; Li,Huiling; Liu,Jun; Guan,Yubao; Huang,Liyan; Tang,Hailing; He,Jianxing

doi:10.3892/ol.2014.2379

Immune reconstitution from peripheral blood mononuclear cells inhibits lung carcinoma growth in NOD/SCID mice

Authors:
- Xiang Liu
- Huiling Li
- Jun Liu
- Yubao Guan
- Liyan Huang
- Hailing Tang
- Jianxing He
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, The Second Hospital Affiliated to University of South China, Hengyang, Hunan 421001, P.R. China, Department of Cardiothoracic Surgery, Guangzhou Institute of Respiratory Disease, State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong 510120, P.R. China, Department of Radiology, Guangzhou Institute of Respiratory Disease, State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong 510120, P.R. China
Published online on: July 24, 2014 https://doi.org/10.3892/ol.2014.2379
Pages: 1638-1644

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Drug resistance and immune deficiency are important factors for the poor prognosis of lung carcinoma. The present study explored the possible protective effect of immune reconstitution from peripheral blood mononuclear cells (PBMCs) on multi‑drug‑resistant human lung carcinoma Am1010 cells in non‑obese diabetic/severe combined immunodeficient (NOD/SCID) mice. The inoculated tumor fragments grew rapidly in the NOD/SCID mice. The growth was significantly inhibited by intraperitoneal injection of PBMCs. In the mice injected with PBMCs, numerous CD3+ and CD8+ cells, but less CD4+ cells, were found in spleen and tumor tissues. These data suggest that PBMC transplantation inhibits lung carcinoma progression via the reconstitution of the immune system, particularly of cytotoxic T lymphocytes.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008.
2	Nadkar A, Pungaliya C, Drake K, Zajac E, Singhal SS and Awasthi S: Therapeutic resistance in lung cancer. Expert Opin Drug Metab Toxicol. 2:753–777. 2006.
3	Levina V, Marrangoni AM, DeMarco R, Gorelik E and Lokshin AE: Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One. 3:e30772008.
4	Wang X, Long M, Dong K, Lin F, Weng Y, Ouyang Y, Liu L, Wei J, Chen X, He T and Zhang HZ: Chemotherapy agents-induced immunoresistance in lung cancer cells could be reversed by trop-2 inhibition in vitro and in vivo by interaction with MAPK signaling pathway. Cancer Biol Ther. 14:1123–1132. 2013.
5	Li HL, Xie SM, Zhang L, Cai CJ, Wang W, Huang J, Wang DY, Wen DP, Deng QH, Zhong NS and He JX: Establishment and characterization of a new drug surviving cell line Am1010, derived directly from muscle metastases of a human lung adenocarcinoma patient with multi-drug-resistance to cisplatin, taxol, and gefitinib. Acta Pharmacol Sin. 31:601–608. 2010.
6	Prestwich RJ, Errington F, Hatfield P, Merrick AE, Ilett EJ, Selby PJ and Melcher AA: The immune system - is it relevant to cancer development, progression and treatment? Clin Oncol (R Coll Radiol). 20:101–112. 2008.
7	Gooden MJ, de Bock GH, Leffers N, Daemen T and Nijman HW: The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 105:93–103. 2011.
8	Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ and Sato E: CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA. 104:3967–3972. 2007.
9	Staibano S, Mascolo M, Tranfa F, Salvatore G, Mignogna C, Bufo P, Nugnes L, Bonavolontà G and De Rosa G: Tumor infiltrating lymphocytes in uveal melanoma: a link with clinical behavior? Int J Immunopathol Pharmacol. 19:171–179. 2006.
10	Nakamura H, Saji H, Ogata A, Hosaka M, Hagiwara M, Kawasaki N, Konaka C and Kato H: Immunologic parameters as significant prognostic factors in lung cancer. Lung Cancer. 37:161–169. 2002.
11	Pelletier MP, Edwardes MD, Michel RP, Halwani F and Morin JE: Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis. Can J Surg. 44:180–188. 2001.
12	Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, McKenna S, Mobraaten L, Rajan TV, Greiner DL, et al: Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol. 154:180–191. 1995.
13	Smit JK, Faber H, Niemantsverdriet M, Baanstra M, Bussink J, Hollema H, van Os RP, Plukker JT and Coppes RP: Prediction of response to radiotherapy in the treatment of esophageal cancer using stem cell markers. Radiother Oncol. 107:434–441. 2013.
14	Yamauchi Y, Izumi Y, Asakura K, Kawai K, Wakui M, Ohmura M, Suematsu M and Nomori H: Lewis lung carcinoma progression is facilitated by TIG-3 fibroblast cells. Anticancer Res. 33:3791–3798. 2013.
15	van der Loo JC, Hanenberg H, Cooper RJ, Luo FY, Lazaridis EN and Williams DA: Nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mouse as a model system to study the engraftment and mobilization of human peripheral blood stem cells. Blood. 92:2556–2570. 1998.
16	Kretz-Rommel A, Qin F, Dakappagari N, Cofiell R, Faas SJ and Bowdish KS: Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J Immunol. 180:699–705. 2008.
17	Xu Y, Sun J, Sheard MA, Tran HC, Wan Z, Liu WY, Asgharzadeh S, Sposto R, Wu HW and Seeger RC: Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1. Cancer Immunol Immunother. 62:1637–1648. 2013.
18	Perdomo C, Campbell JD, Gerrein J, Tellez CS, Garrison CB, Walser TC, Drizik E, Si H, Gower AC, Vick J, Anderlind C, Jackson GR, Mankus C, Schembri F, O’Hara C, Gomperts BN, Dubinett SM, Hayden P, Belinsky SA, Lenburg ME and Spira A: MicroRNA 4423 is a primate-specific regulator of airway epithelial cell differentiation and lung carcinogenesis. Proc Natl Acad Sci USA. 110:18946–18951. 2013.
19	Maes E, Landuyt B, Mertens I and Schoofs L: Interindividual variation in the proteome of human peripheral blood mononuclear cells. PLoS One. 8:e619332013.
20	Dai YQ, Jin DZ, Zhu XZ and Lei DL: Triptolide inhibits COX-2 expression via NF-kappa B pathway in astrocytes. Neurosci Res. 55:154–160. 2006.
21	D’Antonio C, Passaro A, Gori B, Del Signore E, Migliorino MR, Ricciardi S, Fulvi A and de Marinis F: Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol. 6:101–114. 2014.
22	Wang C, Xiao Q, Li YW, Zhao C, Jia N, Li RL, Cao SS, Cui J, Wang L, Wu Y and Wen AD: Regulatory mechanisms of annexin-induced chemotherapy resistance in cisplatin resistant lung adenocarcinoma. Asian Pac J Cancer Prev. 15:3191–3194. 2014.
23	Greiner DL, Shultz LD, Yates J, Appel MC, Perdrizet G, Hesselton RM, Schweitzer I, Beamer WG, Shultz KL, Pelsue SC, et al: Improved engraftment of human spleen cells in NOD/LtSz-scid/scid mice as compared with C.B-17-scid/scid mice. Am J Pathol. 146:888–902. 1995.
24	Hesselton RM, Greiner DL, Mordes JP, Rajan TV, Sullivan JL and Shultz LD: High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to human immunodeficiency virus type 1 infection in NOD/LtSz-scid/scid mice. J Infect Dis. 172:974–982. 1995.
25	Lee YS, Kim TS and Kim DK: T lymphocytes derived from human cord blood provide effective antitumor immunotherapy against a human tumor. BMC Cancer. 11:2252011.
26	Liu H, Zhang T, Ye J, Li H, Huang J, Li X, Wu B, Huang X and Hou J: Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunol Immunother. 61:1849–1856. 2012.
27	Morris M, Platell C and Iacopetta B: Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res. 14:1413–1417. 2008.
28	Lee WS, Kang M, Baek JH, Lee JI and Ha SY: Clinical impact of tumor-infiltrating lymphocytes for survival in curatively resected stage IV colon cancer with isolated liver or lung metastasis. Ann Surg Oncol. 20:697–702. 2013.
29	Batchelder CA, Duru N, Lee CI, Baker CA, Swainson L, Mccune JM and Tarantal AF: Myeloid-lymphoid ontogeny in the rhesus monkey (Macaca mulatta). Anat Rec (Hoboken). May 28–2014.(Epub ahead of print).
30	Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B and Frost P: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 60:397–403. 1990.
31	Rosenberg SA: A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 10:281–287. 1999.
32	Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM and Busund LT: Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res. 14:5220–5227. 2008.
33	Fridman WH, Pagès F, Sautès-Fridman C and Galon J: The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 12:298–306. 2012.
34	Donnem T, Al-Shibli K, Andersen S, Al-Saad S, Busund LT and Bremnes RM: Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer. Cancer. 116:4318–4325. 2010.
35	Ganesan AP, Johansson M, Ruffell B, Beltran A, Lau J, Jablons DM and Coussens LM: Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J Immunol. 191:2009–2017. 2013.